107 related articles for article (PubMed ID: 10556673)
1. The assessment of antagonist potency under conditions of transient response kinetics.
Christopoulos A; Parsons AM; Lew MJ; El-Fakahany EE
Eur J Pharmacol; 1999 Oct; 382(3):217-27. PubMed ID: 10556673
[TBL] [Abstract][Full Text] [Related]
2. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
Grant MK; El-Fakahany EE
J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
[TBL] [Abstract][Full Text] [Related]
3. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
[TBL] [Abstract][Full Text] [Related]
4. Effects of muscarinic toxins MT2 and MT7, from green mamba venom, on m1, m3 and m5 muscarinic receptors expressed in Chinese Hamster Ovary cells.
Bradley KN; Rowan EG; Harvey AL
Toxicon; 2003 Feb; 41(2):207-15. PubMed ID: 12565740
[TBL] [Abstract][Full Text] [Related]
5. Activation of muscarinic acetylcholine receptors elicits pigment granule dispersion in retinal pigment epithelium isolated from bluegill.
González A; Crittenden EL; García DM
BMC Neurosci; 2004 Jul; 5():23. PubMed ID: 15251036
[TBL] [Abstract][Full Text] [Related]
6. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor.
Jakubík J; Tucek S; El-Fakahany EE
J Pharmacol Exp Ther; 2002 Jun; 301(3):1033-41. PubMed ID: 12023535
[TBL] [Abstract][Full Text] [Related]
7. Muscarinic cholinoceptor activation modulates DNA synthesis and CD40 expression in fibroblast cells.
Casanova M; Furlán C; Sterin-Borda L; Borda ES
Auton Autacoid Pharmacol; 2006 Jul; 26(3):293-301. PubMed ID: 16879495
[TBL] [Abstract][Full Text] [Related]
8. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
Jakubík J; El-Fakahany EE; Dolezal V
Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
[TBL] [Abstract][Full Text] [Related]
9. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors.
Huang XP; Nagy PI; Williams FE; Peseckis SM; Messer WS
Br J Pharmacol; 1999 Feb; 126(3):735-45. PubMed ID: 10188986
[TBL] [Abstract][Full Text] [Related]
10. Role of M1 receptor in regulation of gastric fundus smooth muscle contraction.
Gajdus M; Szadujkis-Szadurska K; Szadujkis-Szadurski L; Glaza I; Szadujkis-Szadurski R; Olkowska J
Postepy Hig Med Dosw (Online); 2011 Sep; 65():584-7. PubMed ID: 21918262
[TBL] [Abstract][Full Text] [Related]
11. Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies.
Christopoulos A; Grant MK; El-Fakahany EE
J Pharmacol Toxicol Methods; 2000; 43(1):55-67. PubMed ID: 11091130
[TBL] [Abstract][Full Text] [Related]
12. Modulating activity of M1 receptor to the reaction of ileal smooth muscle.
Glaza I; Szadujkis-Szadurski L; Szadujkis-Szadurski R; Gajdus M; Olkowska J
Postepy Hig Med Dosw (Online); 2011 Aug; 65():478-81. PubMed ID: 21918249
[TBL] [Abstract][Full Text] [Related]
13. Immediate and delayed consequences of xanomeline wash-resistant binding at the M3 muscarinic receptor.
Noetzel MJ; Grant MK; El-Fakahany EE
Neurochem Res; 2009 Jun; 34(6):1138-49. PubMed ID: 19082883
[TBL] [Abstract][Full Text] [Related]
14. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
15. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
Stengel PW; Cohen ML
J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
[TBL] [Abstract][Full Text] [Related]
16. Activation of cerebral function by CS-932, a functionally selective M1 partial agonist: neurochemical characterization and pharmacological studies.
Iwata N; Kozuka M; Hara T; Kanek T; Tonohiro T; Sugimoto M; Niitsu Y; Kondo Y; Yamamoto T; Sakai J; Nagano M
Jpn J Pharmacol; 2000 Nov; 84(3):266-80. PubMed ID: 11138727
[TBL] [Abstract][Full Text] [Related]
17. Selective antagonism activity of alkaloids from bulbs Fritillariae at muscarinic receptors: functional studies.
Lin BQ; Ji H; Li P; Jiang Y; Fang W
Eur J Pharmacol; 2006 Dec; 551(1-3):125-30. PubMed ID: 17027747
[TBL] [Abstract][Full Text] [Related]
18. Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.
Šantrůčková E; Doležal V; El-Fakahany EE; Jakubík J
PLoS One; 2014; 9(2):e88910. PubMed ID: 24558448
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacology of recombinant human M3 and M5 muscarinic receptors expressed in CHO-K1 cells.
Watson N; Daniels DV; Ford AP; Eglen RM; Hegde SS
Br J Pharmacol; 1999 May; 127(2):590-6. PubMed ID: 10385263
[TBL] [Abstract][Full Text] [Related]
20. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.
Lindqvist S; Hernon J; Sharp P; Johns N; Addison S; Watson M; Tighe R; Greer S; Mackay J; Rhodes M; Lewis M; Stebbings W; Speakman C; Evangelista S; Johnson I; Williams M
Br J Pharmacol; 2002 Dec; 137(7):1134-42. PubMed ID: 12429587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
